Heart failure across Asia: Same healthcare burden but differences in organization of care

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:223

Review

Reyes, Eugenio B.¹  Ha, Jong-Won²  Firdaus, Isman³  Ghazi, Azmee Mohd⁴  Phrommintikul, Arintaya⁵  Sim, David⁶  Quynh Nga Vu⁷  Siu, Chung Wah⁸  Yin, Wei-Hsian⁹  Cowie, Martin R.¹⁰ 

[1] Univ Philippines, Cardiol Sect, Dept Internal Med, Philippine Gen Hosp, Manila, Philippines

[2] Yonsei Univ, Div Cardiol, Coll Med, Seoul, South Korea

[3] Univ Indonesia, Fac Med, Dept Cardiol & Vasc Med, Natl Cardiovasc Ctr Harapan Kita, Depok, Indonesia

[4] Natl Heart Inst, Kuala Lumpur, Malaysia

[5] Chiang Mai Univ, Dept Internal Med, Fac Med, Chiang Mai, Thailand

[6] Natl Heart Ctr, Dept Cardiol, Singapore, Singapore

[7] Ha Noi Heart Hosp, Dept Internal Med, Hanoi, Vietnam

[8] Univ Hong Kong, Li Ka Shing Fac Med, Div Cardiol, Dept Med, Hong Kong, Hong Kong, Peoples R China

[9] Natl Yang Ming Univ, Cheng Hsin Gen Hosp, Div Cardiol, Fac Med, Taipei, Taiwan

[10] Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England

关键词: Heart failure;    Asia;    Etiology;    Hospitalization;    Mortality;    Treatment;   

DOI  :  10.1016/j.ijcard.2016.07.256

来源: Elsevier

【 摘 要 】

A gap in the knowledge on the status of heart failure (HF) in Asia versus other regions led to the creation of a working group of Asian experts from 9 countries or regions (Hong Kong, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam). Each expert sought the best available data from local publications, registries, or clinical practice. The prevalence of HF in Asia was generally similar to global values (1% to 3%), but with some outliers. There were substantial variations in healthcare spending, and the average cost of HF hospitalization varied from 813 US$ in Indonesia to nearly 9000 US$ in South Korea. Comorbidities were frequent, particularly hypertension, diabetes mellitus, and dyslipidemia. Modifiable risk factors such as smoking were alarmingly common in some countries. Asian HF patients spent between 5 and 12.5 days in hospital, and 3% to 15% were readmitted for HF by 30 days. The pharmacological treatment of Asian patients generally followed international guidelines, including renin-angiotensin-aldosterone system inhibitors (61% to 90%), diuretics (76% to 99%), beta-blockers (32% to 78%), and digoxin (19% to 53%), with some room for improvement in terms of life-saving therapies. Our review supports implementation of a more comprehensive and organized approach to HF care in Asia. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.

【 授权许可】

Free